NICE rejects NHS funding Sanofi/Regeneron's Dupixent in asth...

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence.

NICE chair nominee Nebhrajani to face MP scrutiny next week

Girl loses High Court battle over NICE review of BioMarin’s ...

NICE backs Celgene’s Revlimid for chemo-free lymphoma therap...

NICE rejects Roche's Polivy combination in advanced lymphoma

England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with a form of advanced lymphoma, NICE has said in first draft g

First UK patients get Novartis’ Luxturna gene therapy for bl...